|Bid||8.41 x 4000|
|Ask||12.41 x 900|
|Day's Range||9.86 - 10.00|
|52 Week Range||5.11 - 13.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.93|
CLEVELAND, Aug. 17, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 18,648,649 shares of common stock at a price to the public of $9.25 per share, for gross proceeds of approximately $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. ViewRay intends to use the net proceeds from the offering for working capital and general corporate purposes, including capital expenditures, research and development expenses, commercial expenses, clinical data generation costs and infrastructure expenses.
CLEVELAND, Aug. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 16,216,217 shares of common stock at a price to the public of $9.25 per share, for gross proceeds of $150 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 2,432,432 shares of common stock at the public offering price, less underwriting discounts and commissions.
CLEVELAND, Aug. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be offered by ViewRay.
In terms of the financials, revenue was well-ahead of our (pre-preannounced Q2) numbers, reflecting one earlier-than-estimated installation (3 A vs 2 E), partially offset by slightly softer than modeled (~15%) average pricing. Both of these differences should dissipate through the end of the year, with management continuing to guide for FY2018 total revenue of $80M - $90M (i.e. Certainly that seems to be consistent with comments on the Q2 call by Scott Drake, the newly appointed CEO.
On August 3, ViewRay (VRAY) reported revenues of $16.4 million for the second quarter of 2018, which is a YoY (year-over-year) rise of 2,248.6%. The performance was driven by the recognition of revenues related to the sale of three MRIdian Linacs for MRI-guided radiation therapy. It also received new orders worth $34.6 million for its MRIdian systems. At the end of the quarter, it had a backlog of orders worth $200 million, which is a YoY rise of 11.1%.
On a per-share basis, the Oakwood Village, Ohio-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
CLEVELAND , Aug. 3, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018 . Second Quarter 2018 Highlights: Total revenue of $16.4 ...
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 3, 2018 at 8:30 AM Eastern Time. To listen ...
CLEVELAND , July 31, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2018 financial results, which will take place on Friday, August ...
Presentations Highlight MRIdian Clinical Experience with On-Table Adaptive Therapy Combined with the Novel Ability to Visualize and Actively Target Tumors that Move CLEVELAND , July 26, 2018 /PRNewswire/ ...
NEW YORK, NY / ACCESSWIRE / July 26, 2018 / Nevro and ViewRay were both big winners in Wednesday's trading session. Nevro announced a patent litigation update that had traders cheering while ViewRay appointed new people to its management team and announced encouraging preliminary results for the second quarter. Nevro Corp. shares closed up 35.71% on almost 5.4 million shares traded.
Traders cheer after the company announces the hiring of a new management team and provides investors with a preliminary look at second-quarter results.
CLEVELAND, July 24, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the market-leading MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott Drake as its President and Chief Executive Officer and Shar Matin as its Chief Operating Officer, effective immediately. In connection with his appointment, Mr. Drake has also been appointed to the ViewRay Board of Directors. In addition, ViewRay announced the appointment of D. Keith Grossman to the ViewRay Board of Directors. ViewRay announced preliminary unaudited revenue of approximately $16 million for the second quarter ended June 30, 2018, primarily from three revenue units, and reaffirmed full year 2018 revenue guidance of $80 million to $90 million.
Stock Research Monitor: WMGI, ZBH, and ARAY LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on VRAY sign up now at www.wallstequities.com/registration . Pre-market today, WallStEquities.com ...
CLEVELAND, July 11, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced that the company's MRIdian® Linac has been selected for installation at Centre Georges-François Leclerc (CGFL) in Dijon, France as part of a tender award contract with UNICANCER, a hospital network of 19 French Comprehensive Cancer Centers (FCCCs). MRIdian Linac combines the latest innovations in precision radiation delivery with ground-breaking MR image guidance. It enables daily real-time on-table adaptive radiotherapy (ROAR™) treatment, allowing clinicians to quickly and dynamically adjust for anatomical changes that may naturally occur each day throughout the patient's course of treatment.
CLEVELAND, July 9, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that Palos Health, in partnership with Loyola Medicine, has installed ViewRay's MRIdian® Linac System for MR image-guided radiation therapy at its Palos Health South Campus in Orland Park, Illinois. Palos Health becomes the first community hospital in the United States, and the only center in Illinois with the company's next generation linear accelerator-based system. MR image-guided radiotherapy represents the latest advance in the field of radiation oncology.
ViewRay (VRAY) used $37.45 million on operating activities in Q1 2018 as compared with $11.96 million in Q1 2017. This change in Q1 2018 over Q1 2017 was attributable to an increase of $12 million in inventory and $3 million on deposits on purchased inventory. The customer deposits and deferred revenue decreased by $18.6 million, while accounts receivable increased by $5.8 million.
This increase was due to higher personnel expenses and consulting fees. Its general and administrative expenses also witnessed an uptrend, rising from $7.15 million in Q1 2017 to $9.84 million in Q1 2018.
ViewRay (VRAY) generates revenues from product sales, services provided, and distribution rights. The company’s services revenue fell from $1.1 million in Q1 2017 to $692,000 in Q1 2018. Its revenue from distribution rights was unchanged at $119,000 in Q1 2018 as compared with Q1 2017. In Q1 2018, ViewRay generated $25.38 million from product sales related to the installation of four MRIdian Linac systems and one system upgrade. The company didn’t generate product revenues in Q1 2017.
ViewRay (VRAY) is focused on manufacturing and commercializing MRIdian, its magnetic resonance (or MR) image-guided radiation therapy system, which uses MRI and external beam radiation therapy to concurrently image and treat cancer patients. In February 2017, it received 510(k) clearance from the Food and Drug Administration (or FDA) to market MRIdian Linac. In July 2018, six of the total seven analysts covering ViewRay have given the stock a “buy” or higher rating, while one analyst has given it a “sell” rating.
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ViewRay, ...
ViewRay Inc (NASDAQ:VRAY), a medical equipment company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. AsRead More...
CLEVELAND, June 21, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, has begun patient treatments with the company's MRIdian® Linac, following an upgrade of the hospital's original MRIdian System. The next-generation MRIdian Linac combines the benefits of MR-image guidance with linear accelerator radiation delivery for the precision treatment of cancer. University of Wisconsin Carbone Cancer Center helped pioneer the field of MR image-guided radiation therapy when they became the second hospital in the world to install the MRIdian System in the summer of 2014.
CLEVELAND, June 13, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, is treating patients with the company's second-generation MR image-guided radiotherapy system, the MRIdian® Linac. Siteman is the first U.S. cancer center to offer cancer therapy with both MRIdian and MRIdian Linac, furthering its leadership role in MR image-guided radiation therapy.